Obviousness

Based on the provided prior art analysis, here is an assessment of the obviousness of US patent 9,549,918 under 35 U.S.C. § 103.

Obviousness Analysis Under 35 U.S.C. § 103

Under United States patent law, an invention is considered obvious if the differences between the invention and the prior art are such that the invention as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis considers the scope of the prior art, the differences between the prior art and the claims, and the level of ordinary skill in the relevant art.

Person Having Ordinary Skill in the Art (PHOSITA)

At the time of this invention (priority date 2008-05-30), a PHOSITA would be a pharmaceutical scientist or formulation chemist with a graduate degree in a relevant field (e.g., pharmaceutics, chemistry) and several years of experience in developing oral dosage forms, particularly for poorly soluble and chemically sensitive compounds. This individual would be familiar with solid dispersion technology, common pharmaceutical excipients including polymers (like PEGs and poloxamers) and pH-modifying agents, and standard methods for drug stability analysis.

Potential Obviousness Combination

A compelling argument for the obviousness of the claims of US 9,549,918 can be constructed by combining the teachings of WO 2005/020993 A1 (Holm) and US 6,372,760 B1 (Kato).

1. Base Reference: WO 2005/020993 A1 (Holm)
   This application, by the same inventors, provides the foundational formulation. It explicitly discloses a solid dispersion of tacrolimus in a vehicle comprising polyethylene glycol (PEG 6000) and poloxamer 188. This is the exact, unstabilized formulation that the '918 patent aims to improve. A PHOSITA would select this reference as a starting point for developing a sustained-release tacrolimus product.

2. Motivation to Modify the Holm Formulation
   A PHOSITA, following standard pharmaceutical development protocols, would conduct stability testing on the formulation described in Holm. As demonstrated in Example 2 of the '918 patent, this base formulation is unstable and leads to significant degradation of tacrolimus into its C8-epimer (8-epitacrolimus). The discovery of this instability would present a clear and well-recognized problem that the PHOSITA would be motivated to solve to create a commercially viable product with an acceptable shelf life.

3. Secondary Reference: US 6,372,760 B1 (Kato)
   Faced with a chemical stability problem, the PHOSITA would search the prior art for known methods of stabilizing drug formulations. Kato expressly teaches the use of an organic acid, specifically mentioning tartaric acid, as a stabilizing agent to prevent the degradation (discoloration) of a different drug, donepezil. Kato provides the clear suggestion that adding an organic acid is a known technique for improving the chemical stability of a pharmaceutical composition.

4. Reason to Combine and Expectation of Success
   The motivation to combine Holm and Kato is straightforward: to solve the stability problem identified in the Holm formulation by applying the known stabilization strategy taught in Kato. A PHOSITA would have a reasonable expectation of success in this endeavor. Using acidic excipients to control pH is a fundamental and common tool in formulation science to enhance drug stability. While Kato addresses a different drug and degradation pathway, it establishes the principle of using tartaric acid as a pharmaceutical stabilizer. A PHOSITA would find it routine to test a small number of well-known, pharmaceutically acceptable organic acids, such as citric acid and tartaric acid, to see if they could resolve the instability of the tacrolimus formulation. The optimization of the acid concentration (as claimed in claim 14) and the confirmation of stability over time (as in claims 10-13) would be the result of routine experimentation, not an inventive leap.

Arguments Against Obviousness

Despite the strong prima facie case for obviousness, the patentee has significant counterarguments:

• Teaching Away: The most powerful counterargument comes from US 4,716,153 A (Morishita). This patent addresses the stability of macrolide antibiotics, the same chemical class as tacrolimus. Morishita teaches that these compounds are unstable in acidic conditions and must be stabilized by adding a basic substance to create a microenvironment with a pH above 7. This directly contradicts the invention of the '918 patent, which requires adding an acidic substance to lower the pH to below 7. A PHOSITA, knowing that macrolides are generally unstable in acid, might be deterred from trying an acidic stabilizer and would instead be guided by Morishita's teaching to use a basic one. This "teaching away" suggests the solution in the '918 patent was non-obvious.

• Unpredictability of the Art: The patentee would argue that drug stabilization is highly unpredictable. There was no reason for a PHOSITA to believe that a method for preventing the discoloration of donepezil (Kato) would be effective at preventing the specific C8-epimerization of tacrolimus in a melted PEG/poloxamer matrix. The '918 patent identifies a novel degradation product (8-epitacrolimus) and provides a specific, unexpectedly effective solution. As shown in the '918 patent's own examples (Example 5), not all acids work; tartaric acid and other chelating organic acids showed superior performance compared to inorganic acids, indicating that the solution was more complex than simple pH adjustment.

Conclusion

A strong case for obviousness can be made by combining the Holm reference, which provides the base formulation, with the Kato reference, which suggests using tartaric acid as a general-purpose stabilizer. A PHOSITA would have been motivated to combine these teachings to solve the inherent instability of the Holm formulation.

However, the "teaching away" nature of the Morishita patent provides a substantial argument for non-obviousness. It suggests that a person skilled in the art would have been discouraged from exploring the very path that led to the invention. The unpredictability of the specific chemical reaction and the superior, non-linear performance of tartaric acid further support the argument that the solution was not a product of mere routine experimentation. Therefore, while a rejection under § 103 is plausible, the patentee possesses strong rebuttal arguments that could overcome such a rejection.